You are here

Article Text

Article menu
Download PDFPDF
Review
Definitive chemoradiation or radiation therapy alone for the management of vulvar cancer
  1. Parul Nafees Barry1,
  2. Diane C Ling2 and
  3. Sushil Beriwal3,4
  1. 1 Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
  2. 2 Department of Radiation Oncology, University of Southern California, Los Angeles, California, USA
  3. 3 Allegheny Health Network, Pittsburgh, Pennsylvania, USA
  4. 4 Varian Medical Systems Inc, Palo Alto, California, USA
  1. Correspondence to Dr Sushil Beriwal, Allegheny Health Network, Pittsburgh, Pennsylvania, USA; sushilberiwal{at}gmail.com

Abstract

Vulvar cancer is rare, and unresectable disease provides a therapeutic conundrum. Although definitive surgery remains the mainstay for curative treatment of vulvar cancer, a minority of patients present with advanced disease for which surgical resection would be extraordinarily morbid. Pre-operative and definitive radiation with radiosensitizing systemic therapy allows such patients an opportunity for cure. In this review, we explore the origins of pre-operative radiation, current treatment standards for pre-operative and definitive chemoradiation, and future directions.

  • vulvar and vaginal cancer
  • radiation oncology
  • radiotherapy
  • intensity-modulated

http://dx.doi.org/10.1136/ijgc-2021-002530

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors PNB, DCL, and SB contributed equally to the planning, writing and development of this review article.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests SB: Elsevier pathway consultant; Xoft DSMBVarian employer. PNB: Elsevier pathway consultant. DCL: None.

    • Provenance and peer review Commissioned; internally peer reviewed.